Nowtransit to issue 85.39% stake for Best Labs acquisition in share exchange

BioScience Health Innovations, Inc.

Nowtransit acquires Best Labs via share exchange; Best shareholders receive 34.37M shares (85.39% post-exchange) for 100% of Best.
Justin Earl resigns as CEO; Darren Lopez (Best CEO) becomes CEO of combined company.
Justin Earl remains on board; Darren Lopez and John Chymboryk appointed directors.
Closing conditions include audited financials and Form 10 filing; target close by Feb 24, 2023.
Best shareholders subject to 12-month lock-up and no registration for 12 months; shares restricted.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BioScience Health Innovations, Inc. entered into Share Exchange Agreement with Best Labs, Inc. and its shareholders (effective 2023-02-13).

Action: entry
Agreement: merger
Counterparty: Best Labs, Inc. and its shareholders
Effective: 2023-02-13

Exact text from the filing

On February 13, 2023, Nowtransit Inc, a Nevada corporation. (the “Company”) entered into a Share Exchange Agreement (the “Exchange Agreement”) with Best Labs, Inc., a Nevada corporation (“Best”) and the shareholders of Best signatory thereto

View on SEC.gov

Browse all material agreements →

BioScience Health Innovations, Inc. filing history →

Source: SEC EDGAR

accession 0001185185-23-000148

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.